C12N 2710/16034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16034 (Use of virus or viral component as vaccine) appears on 118 US grants and 163 published applications in this corpus.
Search patents in C12N- Granted patents
- 118
- Published applications
- 163
- Assignees
- 110
- Inventors
- 305
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 2 | 0 |
| 2001 | 4 | 1 |
| 2002 | 3 | 1 |
| 2003 | 2 | 3 |
| 2004 | 1 | 6 |
| 2005 | 1 | 1 |
| 2006 | 3 | 4 |
| 2007 | 1 | 5 |
| 2008 | 2 | 1 |
| 2009 | 2 | 3 |
| 2010 | 1 | 2 |
| 2011 | 2 | 3 |
| 2012 | 0 | 3 |
| 2013 | 1 | 5 |
| 2014 | 4 | 8 |
| 2015 | 3 | 10 |
| 2016 | 4 | 8 |
| 2017 | 9 | 18 |
| 2018 | 5 | 9 |
| 2019 | 9 | 9 |
| 2020 | 7 | 9 |
| 2021 | 3 | 10 |
| 2022 | 13 | 9 |
| 2023 | 8 | 14 |
| 2024 | 4 | 11 |
| 2025 | 9 | 6 |
| 2026 | 5 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same21 Apr 2026US 12,605,444 B2The Wistar Institute
- Multivalent HVT vector vaccine31 Mar 2026US 12,589,147 B2Intervet Inc.
- Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens6 Jan 2026US 12,514,922 B2Intervet Inc.
- Vaccines for treating SARS infections in cancer patients6 Jan 2026US 12,516,296 B2City of Hope
- Recombinant herpesvirus of turkeys (HVT) and preparation method and use thereof6 Jan 2026US 12,516,353 B2Yangzhou University
- Recombinant marek's disease virus and uses thereof2 Jul 2026US 2026/0183386 A1Ceva Sante Animale
- Cell line for production of marek's disease virus vaccine and methods of making and using the same2 Jul 2026US 2026/0183388 A1Zoetis Services LLC
- Recombinant Non-Pathogenic Marek's Disease Virus Constructs Encoding Infectious Laryngotracheitis Virus and Infectious Bursal Disease Virus Antigens22 Jan 2026US 2026/0021176 A1Intervet Inc.
- Herpesvirus compositions and related methods8 Jan 2026US 2026/0007739 A1Sanofi Pasteur Limited
- Recombinant hvt vectors expressing multiple antigens of avian pathogens and uses thereof30 Oct 2025US 2025/0333766 A1Boehringer Ingelheim Animal Health USA Inc.
Most cited
By later US patents
- Preparation of inactivated viral vaccines92US 4,693,981 AAdvanced Genetics Research Institute · 1987
- Method of inducing a CTL response28US 6,994,851 B1MannKind Corporation · 2006
- Viral nucleotide sequences12US 5,906,821 ARhone Merieux · 1999
- Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer11US 9,107,887 B2Pfizer Inc. · 2015
- Recombinant infectious bovine rhinotracheitis virus10US 6,410,033 B1Syntro Corporation · 2002